safinamide inn brand name xadago drug used addon treatment parkinsons disease episodes multiple modes action including inhibition monoamine oxidase approved european union february united states march canada january safinamide used treat idiopathic parkinsons disease addon people taking stable dose levodopa ldopa alone combination parkinson drugs help episodes levodopa stops safinamide contraindicated people severe liver impairment albinism retinitis pigmentosa severe diabetic neuropathy uveitis disorders retina combination monoamine oxidase mao inhibitors pethidine also safe women take excreted breast milk effects infants common adverse events clinical trials people included nausea dizziness tiredness sleeplessness orthostatic hypotension low blood pressure headache significant difference occurrence effects safinamide experiments rats monkeys retinopathies expected overdose effects hypertension high blood pressure orthostatic hypotension hallucinations psychomotor agitation nausea vomiting dyskinesia studies single person suspected overdosed month symptoms confusion drowsiness mydriasis dilation pupils subsided completely drug discontinued specific antidote mao inhibitor safinamide theoretically cause hypertensive crises serotonin syndrome severe side effects combined mao inhibitors drugs known interact mao inhibitors pethidine dextromethorphan selective serotonin reuptake inhibitors ssris reuptake inhibitors snris tricyclic tetracyclic antidepressants interaction tyramine substance found various foods could expected reasoning excluded safinamide given opioids fatal reactions another theoretical interaction drugs affinity transporter protein also known bcrp pitavastatin pravastatin ciprofloxacin methotrexate diclofenac study latter shown clinical study testing possible interactions amidase inhibitors part postauthorisation development relevant interactions related cytochrome cyp liver enzymes although one inactivation pathway safinamide seems mediated like older antiparkinson drugs selegiline rasagiline safinamide selective monoamine oxidase b inhibitor reducing degradation dopamine contrast two action reversible safinamide also inhibits glutamate dopamine serotonin binds sigma receptors well values binding inhibition nm nm additionally blocks sodium calcium relevance antiparkinson action however safinamide absorbed quickly nearly completely gut reaches highest blood plasma concentrations hours relevant firstpass metabolism total bioavailability substance bound plasma proteins metabolism well understood principal step mediated amidases identified produces safinamide acid relevant metabolites odebenzylated safinamide ndealkylated amine oxidized carboxylic acid glucuronide tests liver microsomes dealkylation seemed mediated cyp enzymes appear involved well safinamide acid binds organic anion transporter probably clinical relevance safinamide transiently binds transporter affinities found preliminary safinamide eliminated mainly form metabolites via kidney elimination halflife hours found compound originally discovered farmitaliacarlo acquired pharmacia pharmacia merged upjohn safinamide first disclosed course major restructuring year rights safinamide transferred newly formed company newron pharmaceuticals developed drug sold merck kgaa phase iii clinical trial started scheduled run october merck merckserono announced would give rights develop compound back newron wanted prioritise projects corrected estimates safinamides market potential us food drug administration fda refused file newrons application formal newron reapplied december spring following commercial agreement newron italian pharmaceutical company zambon european medicines agency ema approved following years drug launched several european safinamide first antiparkinson medication approved ten safinamide approved us fda march people parkinsons taking levodopacarbidopa potential additional uses might restless legs syndrome rls safinamide tested phase ii trials results available used adjunct parkinsonian medication safinamide found efficacious reducing pain httpsenwikipediaorgwikisafinamide